Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells

BACKGROUND: Although pioglitazone, a well‐known anti‐diabetic agent, has recently established itself as a pillar of cancer treatment, its therapeutic value could be attenuated by the aberrant activation of the PI3K/Akt pathway. AIM: To evaluate whether the PI3K/Akt suppression in leukemic cells coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Esmaeili, Shadi, Yousefi, Amir‐Mohammad, Delshad, Mahda, Bashash, Davood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009912/
https://www.ncbi.nlm.nih.gov/pubmed/36398521
http://dx.doi.org/10.1002/mgg3.2106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009912/
https://www.ncbi.nlm.nih.gov/pubmed/36398521
http://dx.doi.org/10.1002/mgg3.2106

Ejemplares similares